Abstract: Primary immune thrombocytopenia（ITP）is an acquired autoimmune hemorrhagic disease.The incidence of ITP in adults is about（2-10）/100 000.ITP during pregnancy is a common cause of pregnancy with thrombocytopenia，accounting for about 3%-5%.It is mainly manifested as thrombocytopenia in early pregnancy.The basic principle of the treatment for ITP during pregnancy is preventing maternal and neonatal adverse bleeding events.The first-choice treatment is drug therapy，including glucocorticoids，recombinant human thrombopoietin，etc.The management of ITP during pregnancy must run throughout pregnancy，focusing on pre-conception counseling，monitoring and treatment during pregnancy，selection of delivery timing and mode，and neonatal platelet testing.

Key words: primary immune thrombocytopenia, thrombocytopenia, long-term management

摘要： 原发免疫性血小板减少症（ITP）是一种获得性自身免疫性出血性疾病，成人ITP的发病率约为（2~10）/10万。妊娠合并ITP是妊娠期血小板减少的常见病因，约占3%~5%，主要表现为妊娠早期的血小板减少。妊娠合并ITP的治疗方法以减少母体及新生儿不良出血事件为基本原则，首选药物治疗。治疗药物包括糖皮质激素、重组人血小板生成素等。妊娠合并ITP的管理须贯穿妊娠全程，其中孕前咨询、孕期监测与治疗、分娩时机和分娩方式的选择、新生儿血小板检测均需重点关注。

关键词: 原发免疫性血小板减少症, 孕产期血小板减少, 长期管理